AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

ERYTECH Pharma S.A.

Declaration of Voting Results & Voting Rights Announcements Aug 4, 2017

1295_dva_2017-08-04_78ef2b55-4c62-42bd-a929-a9023abe54d3.pdf

Declaration of Voting Results & Voting Rights Announcements

Open in Viewer

Opens in native device viewer

Information related to total number of voting rights and shares composing the share capital –July 31st , 2017

Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon - France

Listing market: Euronext Paris from Euronext Market segment : segment C

ISIN Code : FR0011471135

website : www.erytech.com

Date Total of shares composing
the share capital
Total of brut(1) voting
rights
Total of net(2) voting
rights
January 1st, 2017 8 732 648 10 410 050 10 407 550
February 28, 2017 8 732 648 10 395 830 10 393 330
March 31, 2017 8 734 698 10 351 950 10 349 450
April 19, 2017 11 740 648(3) 13 303 800 13 301 300
April 30, 2017 11 743 148(4) 13 303 549 13 301 049
May 31, 2017 11 744 148(4) 13 304 550 13 302 050
June 30, 2017 11 744 448(4) 13 298 756 13 296 256
July 31,2017 11 744 448 13 300 266 13 297 766

(1) Gross voting rights number (or « theoretical » voting rights) is used as a calculus base for the crossing of the threshold. In accordance with article 223-11 of general regulation of Autorité des Marchés Financiers, this number is calculated on the basis of all shares carrying the single and double voting rights, including shares without voting rights.

(2) Without treasury shares

(3) The number of shares and voting rights raised following the issuance of 3 000 000 new shares (cf. Note d'opération Visa n°17-161 available on the Company's website)

(4) The number of shares increased due to issuance of shares consequently to warrants exercises which a Board of Director will take notice of in the future.

Talk to a Data Expert

Have a question? We'll get back to you promptly.